DOSSIER · UPDATED 18 NOV 2025

Be Biopharma

Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

be.bio ↗Claim this profile
Founded
2020
Headcount
71
Open roles
0
Last raised
Series C · $92M
SECTION I · THE BRIEF

Inside Be Biopharma

Brief #34517Updated 18 NOV 2025CAMBRIDGEMEDICAL ORGANIZATIONSSERIES C
Employbl Dossier

Be Biopharma

Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

Founded
2020
Headcount
71
Open roles
0
Last raised
Series C · $92M
Section II — RestrictedMembers only
  • Tech stack (Be Biopharma engineering primaries)
  • Hiring focus this quarter
  • Interview format & rubric
  • Comp bands by level
  • Decision-makers in talent
  • Recent news & moves
Open Be Biopharma briefSign in

7-day free trial · $25/mo · cancel anytime

TAGS

Categorized in

Company Collections

These are collections Be Biopharma is a part of. Click on the collection name to view similar companies.

Be Biopharma's Industries

Be Biopharma's Tech Stack

LOCATIONS

Where they work

Be Biopharma Headquarters Location

B200 Suite 001, Cambridge, MA, 02139

Loading map…
FUNDING

Capital raised

Total Amount Raised: $356,000,000

Be Biopharma Funding Rounds

  • Series C

    $92,000,000

  • Series C

    $92,000,000

    Series C Investors

    Bristol Myers Squibb
    Longwood Fund
    Nextech Invest
    Arch Venture Partners
    Atlas Venture
    Alta Partners
    RA Capital Management
    Takeda Ventures

  • Series Unknown

    $82,000,000

  • Series Unknown

    $82,000,000

    Series Unknown Investors

    Arch Venture Partners
    Takeda Ventures
    RA Capital Management
    Atlas Venture
    Alta Partners
    Bristol Myers Squibb
    Longwood Fund

  • Series B

    $130,000,000

  • Series B

    $130,000,000

    Series B Investors

    Arch Venture Partners
    Takeda Ventures
    Longwood Fund
    RA Capital Management
    Alta Partners
    Atlas Venture
    Bristol Myers Squibb

  • Series A

    $52,000,000

  • Series A

    $52,000,000

    Series A Investors

    Atlas Venture
    RA Capital Management
    Takeda Ventures
    Longwood Fund
    Alta Partners
Funding info provided by Diffbot.
EMPLOYEE REVIEWS

On the ground at Be Biopharma

Be Biopharma Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Be Biopharma.

Recent reviews